MCB-613 exploits a collateral sensitivity in drug resistant EGFR-mutant non-small cell lung cancer through covalent inhibition of KEAP1.
Bassil CF, Anderson GR, Mayro B, Askin KN, Winter PS, Gruber S, Hall TM, Hoj JP, Cerda-Smith C, Hutchinson HM, Killarney ST, Singleton KR, Qin L, Jubien-Girard K, Favreau C, Martin AR, Robert G, Benhida R, Auberger P, Pendergast AM, Lonard DM, Puissant A, Wood KC.
Bassil CF, et al. Among authors: mayro b.
bioRxiv [Preprint]. 2023 Jan 19:2023.01.17.524094. doi: 10.1101/2023.01.17.524094.
bioRxiv. 2023.
PMID: 36711936
Free PMC article.
Preprint.